ROCKVILLE, Md., Feb. 26,
2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for
the fourth quarter and full year ended December 31, 2024, and recent operational
highlights.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company's investor website approximately two hours after the call's
conclusion. Those who plan on participating are advised to join 15
minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. Since its founding
in 2009, REGENXBIO has pioneered the development of AAV
Therapeutics, an innovative class of gene therapy
medicines. REGENXBIO is advancing a pipeline of AAV
Therapeutics for rare and retinal diseases, including RGX-202 for
the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet
AMD and diabetic retinopathy, being developed in collaboration with
AbbVie, and RGX-121 for the treatment of MPS II. Thousands of
patients have been treated with REGENXBIO's AAV
Therapeutic platform, including Novartis'
Zolgensma® for children with spinal muscular
atrophy. Designed to be one-time treatments, AAV Therapeutics have
the potential to change the way healthcare is delivered for
millions of people. For more information, please visit
WWW.REGENXBIO.COM.
Contacts:
Dana
Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-13-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-recent-operational-highlights-302385846.html
SOURCE REGENXBIO Inc.
